ProAxsis Gains CE Mark for Active Neutrophil Elastase Immunoassay
Belfast, Northern Ireland, 30th September 2016 / Sciad Newswire / ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay. Neutrophil Elastase is a well-recognised biomarker of lung inflammation and infection in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis. The registration of a CE Mark indicates that the ProteaseTag® Active Neutrophil Elastase Immunoassay complies with EU legislation, and enables the company to commercialise the Immunoassay throughout the European market.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “This is a very proud day for everyone at ProAxsis, with the successful registration of our first CE Mark. We have already had enquiries from a number of pharmaceutical companies concerning the commercial use of our ProteaseTag® Active Neutrophil Elastase Immunoassay in their upcoming clinical trials, and look forward to making the assay more widely available to the respiratory community now that it has its CE Mark. I would particularly like to acknowledge the work of Dr Charlene Robb, who has led the regulatory efforts that have enabled us to reach this significant milestone.”
Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to email@example.com.
About ProAxsis Limited
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. This test measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) and an important drug target. The rapid and easy-to-use tests incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
For more information contact
Dr David Ribeiro
T: +44 (0)28 9073 0444
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.